RU2710271C1 - Method for preparing agent for treating inflammatory diseases of upper and lower airways - Google Patents

Abstract

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for preparing an agent for treating inflammatory diseases of the upper and lower airways. Method for preparing an agent for treating inflammatory diseases of upper and lower airways, by grinding plant material to nanopowder, wherein aspen bark (Populus tremula L) is ground to particle size of 1–2 mm, dried to moisture content of 8–10 %, nanodispersed in roller-type mill to particle size of 50–150 nm, then subjected to continuous extraction by repercolation, combined solution after settling is concentrated in vacuum to 70 % of dry substances at temperature of 50 °C with subsequent drying of the powder in vacuum to 3.8–5.5 wt. % content of salicin, arabinogalactanes 4.2–10.1 wt. %, polyphenols 3.9–7.2 wt. %.

EFFECT: method described above enables to obtain an agent with high output of a complex of biologically active substances, high efficiency of treating respiratory organs in upper and lower airway damages, fewer side effects, high availability of biologically active substances.

1 cl, 2 ex

Description

The invention relates to medicine and herbal medicine, and in particular to methods for producing herbal medicines, and can be used in complex pharmacotherapy for the treatment of respiratory organs.

Respiratory tract lesions occupy a leading place in the infectious pathology of various organs and systems, are traditionally the most massive among the population, which affects both adults and children. Infection, as a rule, occurs by airborne droplets, as a result of which the infection settles in the respiratory system.

Respiratory tract infections are acute diseases that occur as a result of the ingestion of infectious agents using the aerogenic mechanism of infection, that is, they are contagious, affecting the respiratory system both primary and secondary, accompanied by inflammatory phenomena and characteristic clinical symptoms.

The main cause of respiratory diseases is microorganisms (bacteria, viruses, fungi, less often parasites). The leading role is played by such bacterial pathogens as: pneumococci, hemophilus bacillus, mycoplasmas, chlamydia, legionella (these pathogens cause mainly pneumonia), mycobacterium tuberculosis, influenza viruses type A and B. Most often, the disease is caused by one type of pathogen (monoinfection), but sometimes (advanced age, AIDS and other immunodeficiency diseases) there may be several (mixed infections).

Conventionally, all diseases of the respiratory tract can be divided into infections of the upper or lower sections. The most common of them: pharyngitis, laryngitis, and sinusitis, various inflammation of the pharynx. The most common lower respiratory tract diseases include pneumonia, bronchitis, and tuberculosis. In addition, some of these diseases can affect both the upper respiratory tract and the lower.

Many synthetic medications have been developed for the treatment of any respiratory diseases. Their disadvantages are the rapid emergence of drug resistance to these drugs, the appearance of various toxic reactions from the liver, gastrointestinal tract and nervous system, and the weakening of the immune status.

The most serious diseases affecting the respiratory tract include bronchitis, pneumonia and tuberculosis. Modern pharmacotherapy of respiratory diseases is based on the integrated use of antibacterial drugs and immunostimulants, hormonal drugs and mucolytic agents. Their action is usually accompanied by side effects, the severity of which increases with their combined use. All this necessitates the search for new safe means.

To prevent or reduce side effects that occur during pharmacotherapy of respiratory diseases, medicinal plants, such as coltsfoot, oregano, licorice, ledum and fees based on them (Pat. 2013094) allow. During the complex therapy of pulmonary tuberculosis, pneumonia, bronchitis, phytocompositions are additionally used, used against the background of antibiotic therapy or independently (US Pat. No. 2223107, 2362577, 2174402). The proposed funds are obtained mainly by preparing water decoctions, extracts or infusions from components of plant origin, which have known anti-allergic, expectorant, anti-inflammatory, antimicrobial, detoxification properties, taken in ratios that provide the necessary therapeutic effect.

Closest to the proposed is a method of obtaining funds with antipyretic effect (RF patent No. 2431495), in which the aspen bark is dried to a residual moisture content of 10-12 wt. %, crushed in planetary type mills, providing acceleration of grinding media, such as balls, up to 400 m / s2 in air for 8-18 s to sizes of 50-90 nm.

The effectiveness of this method is insufficient, since the availability of biologically active substances is small, they are not completely recovered in the target product.

The objective of the invention is the creation of an effective way to obtain funds for the treatment of respiratory organs from plant materials, in which a product is obtained that does not have a toxic effect on the body, reduces and prevents side effects when used in complex treatment, improves the functional state of the respiratory system, increases the efficiency of its biological effects on the body (bioavailability).

The technical result consists in increasing the yield of a complex of biologically active substances, increasing the effectiveness of treatment of respiratory organs with damage to the upper and lower respiratory tract, reducing side effects, increasing the availability of biologically active substances.

The method consists in continuous extraction by repercolation of aspen bark, which is ground in a knife mill to a particle size of 1-2 mm, after drying to a moisture content of 8-10%, nanodispersed in a roller type mill to a particle size of 50-150 nm, then subjected to extraction by repercolation , the combined extract after settling is concentrated in vacuo to 70% solids at a temperature of 50 ° C, followed by drying to a dry powder in vacuum. The resulting product is able to integrate into the cell wall and penetrate into the cells of mycobacteria, disrupting their metabolism, which leads to the death of microorganisms. Phenol glycosides (salicin, salicortin, tremuloidin, tremulacin) inhibit the activity of the central transcription factor of inflammation and act as a hepatoprotector due to antioxidant properties. Arabinogalactans have an immunotropic effect, have an activating effect on macrophage cells, stimulating phagocytosis. Polyphenols have an antimicrobial effect, the antiviral activity and antioxidant properties of polyphenols are also proven.

Aspen bark (Populus tremula L) is subjected to continuous extraction by repercolation in a battery of three percolators. Aspen bark collected during sap flow is pre-crushed in a knife mill to a particle size of 1-2 mm, after drying to a moisture content of 8-10%, it is nanodispersed in a roller-type mill, providing grinding to a particle size of 50-150 nm. The grinding of raw materials allows you to completely destroy the intermolecular and inter-aggregate bonds of the components and transfer biologically active substances into a free state, which during subsequent extraction increases the yield of the target product with an increased content of active substances. The yield of the target product is 21-26% wt. The content of salicin is 3.8-5.5% by weight, arabinogalactans 4.2-10.1% by weight, polyphenols 3.9-7.2% by weight.

The study of the specific activity of the proposed tool for the treatment of respiratory organs showed that the proposed tool has antibacterial, hepatoprotective, anti-inflammatory, immunotropic effects due to the complex action of biologically active substances isolated from aspen bark (Populus tremula L), increased bioavailability. Example 1. 30 kg of aspen bark (Populus tremula L), collected during sap flow, is ground in a knife mill to a size of 1-2 mm, dried to a moisture content of 8-10%, nanodispersed in a roller-type mill, grinding to a particle size of 50- 150 nm, loaded into the battery of 3 percolators of 10 kg The extraction process by repercolation occurs at a temperature of 70 ° C. The combined extract after settling is concentrated in vacuo to 70% solids at a temperature of 50 ° C, followed by drying to dry powder in vacuo. The yield of the target product is 8.4 kg (28.3% wt.). The content of salicin is 3.8% by weight, the content of arabinogalactans is 4.2% by weight, polyphenols are 3.9% by weight.

Example 2. 30 kg of aspen bark (Populus tremula L) is crushed to a size of 1-2 mm in a knife mill, after drying to a moisture content of 8-10%, nanodisperse in a roller type mill, providing grinding to a particle size of 50-150 nm., Load into a battery of 3 percolators of 10 kg. The extraction process by repercolation occurs at a temperature of 70 ° C. The combined extract after settling, concentrated in vacuo to 70% solids at a temperature of 50 ° C, followed by drying to dry powder in vacuum. The yield of the target product 10.3 kg (34.3% wt.). The content of salicin is 5.5% by weight, the content of arabinogalactans is 10.1% by weight, polyphenols are 7.2% by weight.

Thus, the proposed tool has antimicrobial, anti-inflammatory, antitussive, hepatoprotective and immunotropic effects, which allows it to be used for any respiratory diseases.

Claims (1)

A method of obtaining funds for the treatment of inflammatory diseases of the upper and lower respiratory tract, by grinding plant materials to a nanopowder state, characterized in that the aspen bark (Populus tremula L) is crushed to a particle size of 1-2 mm, dried to a moisture content of 8-10%, nanodispersed in a roller mill to a particle size of 50-150 nm, then subjected to continuous extraction by repercolation, the combined extract after settling is concentrated in vacuum to 70% solids at a temperature of 50 ° C, followed by drying of the powder in vacuum IU to content in salicin means 3,8-5,5 wt.%, arabinogalactans 4,2-10,1% wt., 3,9-7,2% by weight of polyphenols.